Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIN 3248

Next Previous
X
Search
Drug Profile

KIN 3248

Alternative Names: KIN-3248

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kinnate Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cholangiocarcinoma; Solid tumours; Urogenital cancer

Most Recent Events

  • 03 Apr 2024 Kinnate Biopharma has been acquired by XOMA
  • 18 Sep 2023 Efficacy, safety and pharmacodynamics data from a phase I/Ib trial in Solid tumours, Cholangiocarcinoma, Urogenital cancer released by Kinnate Biopharma
  • 14 Feb 2023 KIN 3248 receives Fast Track designation for Cholangiocarcinoma [PO] (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top